NCT06626074Recruiting
Exploratory Study of MRI Biomarkers of NASH
Source: ClinicalTrials.gov · Last updated 16 Jun 2026
Brief summary (registry, in English)
Metabolic steatosis disease (NAFLD) is a rapidly growing disease in the world, particularly in industrialized countries. NAFLD is defined by the presence of fatty liver disease. This is a reversible phenomenon that can be estimated by non-invasive means, such as ultrasound. Non-invasive quantification, on the other hand, requires MRI. Nonalcoholic steatohepatitis (NASH) is the aggressive form of the disease that promotes the accumulation of fibrosis in the liver, which can progress to cirrhosis and its complications. Currently there is no non-invasive biomarker of NASH and the diagnosis is based solely on liver biopsy. There is therefore a need for non-invasive biomarkers of NASH in patients with steatosis to diagnose NASH without the use of liver biopsy.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 110 (estimated)
- First submitted
- 1 Oct 2024
- Start date
- 5 Sept 2025
- Primary completion date
- 5 Sept 2027
- Lead sponsor
- University Hospital, Angers
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT06626074
What you commit to
- Study type: Interventional
- Planned participants: 110
- From 5 Sept 2025 to the primary completion date, 5 Sept 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Person under compulsion to psychiatric care
Other
- Contraindication to MRI
- Time between the establishment of the Steatosis/NASH status and the MRI greater than 3 months
- Pregnant, parturient and breastfeeding woman
- Person deprived of liberty by judicial or administrative decision
- Person subject to a legal protection measure
- Person not affiliated or not covered by a social security scheme.
Who the study is looking for
- Patient included in the SNIFF cohort of the Angers hospital where there is a suspicion of NASH requiring a biopsy for which an MRI is requested by a hepatologist as part of the initial assessment of the disease.
- Adult patient
- Free, informed and express (oral) consent of the patient to participate in the study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Angers Coordinator of this site? Confirm its status | Angers | France | Recruiting |
| CHU de Rennes Coordinator of this site? Confirm its status | Rennes | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.